CN Bio
CN Bio is a close-knit team of passionate scientists, engineers and creative thinkers, all working together towards a shared goal – a future where drugs are discovered more quickly, brought to patients more cost-effectively and with less animal experimentation. Day to day, their cohesive team design, manufacture, promote and support organ-on-a-chip solutions that enable their customers to do something incredible – recreate three-dimensional human organs and tissues in the laboratory to improve understanding of human physiology, disease and the effectiveness of new drugs.
Latest CN Bio Content
Article
A Reflection on Global Fatty Liver Day 2024: How Organ-on-a-Chip Addresses R&D Challenges
To commemorate Global Fatty Liver Day, this article explores how organ-on-a-chip models are transforming liver disease research.
Product News
CN Bio and Altis Biosystems Partner To Develop Next-Generation Human Gut/Liver In Vitro Model
Strategic partnership harnesses respective organ-specific expertise to provide complete human-derived Organ-on-a-Chip solution for more accurate in vitro ADME predictions.
Product News
CN Bio PhysioMimix Organ-on-a-Chip Data Supports Inipharm’s INI-822 for Metabolic Liver Disease Treatment
PhysioMimix NASH assay used to provide human-relevant data on compound efficacy for Inipharm’s lead candidate, INI-822.
Product News
CN Bio and LifeNet Health LifeSciences Partner To Supply Validated Primary Human Cells for Microphysiological Systems
A new partnership to provide customers with direct access to highly characterized hepatic cells to recreate advanced Liver-on-a-Chip assays. These will alleviate the need for stringent in-house quality control testing to maximize assay success.
Product News
CN Bio Extends Microphysiological System Portfolio
CN Bio has announced the commercial launch of the PhysioMimix™ Single-organ Higher Throughput System.
Product News
The FDA Expands Collaboration With CN Bio To Evaluate Multi-Organ Microphysiological System
The U.S. Food and Drug Administration and CN Bio have expanded their collaboration for the second time, with new research aiming to evaluate multi-organ MPS and their applications using the PhysioMimix™ Multi-organ System.
Product News
CN Bio Appoints Dr Paul Brooks as Chief Executive Officer
CN Bio has announced the appointment of Dr Paul Brooks, formerly the Company’s Chief Business Officer, to the position of CEO with immediate effect.
Webinar
The Human Touch: How Liver-on-a-Chip Addresses the Unmet Needs of Liver Disease Research
On-Demand
Join the webinar to learn how:
• Liver disease progresses from a dysregulation of metabolism
• Lipid metabolism differs between mice and men and the impact this has on drug development
• Primary human NASH models can evaluate drugs that target metabolism
• NASH models allow the quantitation of lipid droplets, metabolism and fibrosis
• Liver disease progresses from a dysregulation of metabolism
• Lipid metabolism differs between mice and men and the impact this has on drug development
• Primary human NASH models can evaluate drugs that target metabolism
• NASH models allow the quantitation of lipid droplets, metabolism and fibrosis
Product News
CN Bio Opens New Laboratory Facilities To Extend Organ-on-a-Chip Contract Research Services Capabilities
CN Bio today announced the opening of new laboratory facilities at Cambridge Science Park, dedicated to its contract research services.
Industry Insight
Bridging the Gap Between In Vitro and Animal Models of Liver Disease
We spoke to Dr. Audrey Dubourg, product manager at CN Bio to find out more about how its organ-on-chip platform could bridge the gap between the current 2D models and animal models, providing human-relevant insights into diseases such as non-alcoholic steatohepatitis.
Advertisement
